| 1 | the patient journey from | | | | | | | 4 | 1.16% |
| 2 | across the patient journey | | | | | | | 4 | 1.16% |
| 3 | are purposebuilt to confidently | | | | | | | 3 | 0.87% |
| 4 | tests are purposebuilt to | | | | | | | 3 | 0.87% |
| 5 | of tests are purposebuilt | | | | | | | 3 | 0.87% |
| 6 | suite of tests are | | | | | | | 3 | 0.87% |
| 7 | genetics tpmt enzyme thiopurine | | | | | | | 3 | 0.87% |
| 8 | tpmt enzyme thiopurine metabolites | | | | | | | 3 | 0.87% |
| 9 | enzyme thiopurine metabolites celiac | | | | | | | 3 | 0.87% |
| 10 | through remission the prometheus | | | | | | | 3 | 0.87% |
| 11 | and through remission the | | | | | | | 3 | 0.87% |
| 12 | monitoring and through remission | | | | | | | 3 | 0.87% |
| 13 | disease monitoring and through | | | | | | | 3 | 0.87% |
| 14 | treatment disease monitoring and | | | | | | | 3 | 0.87% |
| 15 | thiopurine metabolites celiac celiac | | | | | | | 3 | 0.87% |
| 16 | metabolites celiac celiac plus | | | | | | | 3 | 0.87% |
| 17 | celiac celiac plus celiac | | | | | | | 3 | 0.87% |
| 18 | journey from diagnosis to | | | | | | | 3 | 0.87% |
| 19 | disease monitr ibd sgi | | | | | | | 3 | 0.87% |
| 20 | purposebuilt to confidently guide | | | | | | | 3 | 0.87% |
| 21 | confidently guide patient care | | | | | | | 3 | 0.87% |
| 22 | to confidently guide patient | | | | | | | 3 | 0.87% |
| 23 | drug monitoring anser ifx | | | | | | | 3 | 0.87% |
| 24 | inflammatory bowel disease monitr | | | | | | | 3 | 0.87% |
| 25 | ust inflammatory bowel disease | | | | | | | 3 | 0.87% |
| 26 | anser ust inflammatory bowel | | | | | | | 3 | 0.87% |
| 27 | vdz anser ust inflammatory | | | | | | | 3 | 0.87% |
| 28 | anser vdz anser ust | | | | | | | 3 | 0.87% |
| 29 | anser ifx anser ada | | | | | | | 3 | 0.87% |
| 30 | monitoring anser ifx anser | | | | | | | 3 | 0.87% |
| 31 | therapeutic drug monitoring anser | | | | | | | 3 | 0.87% |
| 32 | decisions precisionguided dosing about | | | | | | | 3 | 0.87% |
| 33 | adalimumab therapeutic drug monitoring | | | | | | | 3 | 0.87% |
| 34 | maintenance adalimumab therapeutic drug | | | | | | | 3 | 0.87% |
| 35 | diagnostic crohn’s prognostic riskimmune | | | | | | | 3 | 0.87% |
| 36 | crohn’s prognostic riskimmune thiopurine | | | | | | | 3 | 0.87% |
| 37 | prognostic riskimmune thiopurine management | | | | | | | 3 | 0.87% |
| 38 | about predictrpk infliximab induction | | | | | | | 3 | 0.87% |
| 39 | dosing about predictrpk infliximab | | | | | | | 3 | 0.87% |
| 40 | precisionguided dosing about predictrpk | | | | | | | 3 | 0.87% |